Sarepta Therapeutics (SRPT) Research & Development (2016 - 2025)
Historic Research & Development for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $204.4 million.
- Sarepta Therapeutics' Research & Development rose 1374.7% to $204.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.2 billion, marking a year-over-year increase of 5960.8%. This contributed to the annual value of $804.5 million for FY2024, which is 830.48% down from last year.
- Per Sarepta Therapeutics' latest filing, its Research & Development stood at $204.4 million for Q2 2025, which was up 1374.7% from $600.0 million recorded in Q1 2025.
- In the past 5 years, Sarepta Therapeutics' Research & Development registered a high of $600.0 million during Q1 2025, and its lowest value of $139.1 million during Q3 2021.
- Its 5-year average for Research & Development is $229.7 million, with a median of $202.4 million in 2024.
- In the last 5 years, Sarepta Therapeutics' Research & Development tumbled by 2695.0% in 2021 and then soared by 19940.72% in 2025.
- Over the past 5 years, Sarepta Therapeutics' Research & Development (Quarter) stood at $197.3 million in 2021, then grew by 8.37% to $213.8 million in 2022, then decreased by 8.55% to $195.5 million in 2023, then increased by 2.27% to $200.0 million in 2024, then rose by 2.22% to $204.4 million in 2025.
- Its Research & Development stands at $204.4 million for Q2 2025, versus $600.0 million for Q1 2025 and $200.0 million for Q4 2024.